recurrent pneumonia: recurrent pneumonia due to nontuberculous mycobacterium infections
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
495 |
4. Check minimum number of eventsNone |
495 |
5. Include endpointsNone |
495 |
6. Filter based on genotype QC (FinnGen only) |
437 |
Control definitions (FinnGen only)
- Control exclude
- ASTHMA_PNEUMONIA
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- A31
- Name in latin
- Infectio pulmonalis mycobacterialis
Similar endpoints
↥List of similar endpoints to
Atypical mycobacterium lung infection
based on the number of shared cases.
Similar with more cases:
- Pneumonias (Asthma/COPD co-morbidities)
- COPD/asthma/ILD related pneumonia or pneumonia derived septicaemia
- COPD/asthma related pneumonia or pneumonia derived septicaemia
- COPD/asthma/ILD related infections
- COPD/asthma related infections
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3018 | 1576 | 1387 |
| Only index persons | 2203 | 1277 | 926 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.05 | 0.04 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 68.38 | 71.46 | 64.83 |
| Only index persons | 67.81 | 70.61 | 63.93 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 437 | 247 | 190 |
| Unadjusted period prevalence (%) | 0.09 | 0.09 | 0.09 |
| Median age at first event (years) | 68.64 | 68.06 | 69.40 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 451
- Matched controls
- 4510
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A31.0
ICD-10 Finland
Pulmonary mycobacterial infection
4503599627370496.0
307.7
429
*
J47
ICD-10 Finland
Bronchiectasis
80.0
297.9
164
32
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
26.1
218.6
173
105
UGC12
NOMESCO Finland
Flexible bronchoscopy
19.6
218.2
217
204
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
14.6
183.6
230
301
R03BB04
ATC
tiotropium bromide; inhalant
15.7
181.9
203
224
TGC00
NOMESCO Finland
Bronchial lavation
20.9
122.1
99
60
J01MA14
ATC
moxifloxacin; systemic
11.1
116.7
150
193
R03AK06
ATC
salmeterol and fluticasone; inhalant
9.3
116.1
189
325
J18.9
ICD-10 Finland
Pneumonia, unspecified
8.4
113.3
297
840
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
8.4
113.0
219
455
GD1AD
NOMESCO Finland
Thorax CT examination
11.6
108.4
131
154
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
14.8
103.2
101
86
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
16.8
91.9
82
59
R03DA04
ATC
theophylline; systemic, rectal
11.9
91.4
104
111
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
7.9
86.2
149
266
J45.9
ICD-10 Finland
Asthma, unspecified
6.5
78.9
180
421
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
7.6
76.5
132
233
R04.2
ICD-10 Finland
Haemoptysis
13.3
75.5
77
69
R03AC12
ATC
salmeterol; inhalant
11.0
70.6
82
89
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
13.6
68.6
68
58
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
13.9
68.4
67
56
J01MA12
ATC
levofloxacin; systemic
5.5
68.3
192
533
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
8.7
68.1
98
140
J45.0
ICD-10 Finland
Predominantly allergic asthma
8.7
65.7
94
133
J45.1
ICD-10 Finland
Nonallergic asthma
8.7
64.3
91
127
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.2
53.0
346
1756
R03DC03
ATC
montelukast; oral
5.2
52.4
136
344
R03AC02
ATC
salbutamol; inhalant
4.9
50.5
342
1757
R03BA05
ATC
fluticasone; inhalant
4.7
48.3
148
426
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
4.3
46.8
318
1603
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
7.7
46.0
70
105
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
7.6
44.7
69
105
R81
ICPC
Pneumonia
9.9
44.6
54
61
H02AB06
ATC
prednisolone; systemic
4.1
43.9
311
1588
R03AC03
ATC
terbutaline; inhalant
4.9
43.6
116
296
J46
ICD-10 Finland
Status asthmaticus
16.9
42.2
36
23
J96.1
ICD-10 Finland
Chronic respiratory failure
12.1
41.2
43
39
A31.9
ICD-10 Finland
Mycobacterial infection, unspecified
434.5
40.8
40
*
R03AK03
ATC
[U] fenoterol and ipratropium bromide
6.6
39.8
70
122
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.7
36.9
160
578
R03AK08
ATC
formoterol and beclometasone; inhalant
8.1
36.8
52
71
H02AB04
ATC
methylprednisolone; systemic
4.1
36.3
123
374
J45.8
ICD-10 Finland
Mixed asthma
13.5
36.2
35
28
R03BA01
ATC
beclometasone; inhalant
4.2
35.2
114
335
R03AC13
ATC
formoterol; inhalant
6.6
33.0
57
97
R03BB01
ATC
ipratropium bromide; inhalant
6.4
33.0
59
104
XG410
NOMESCO Finland
Flow-volume spirometry
7.1
31.4
50
78
H02AB07
ATC
prednisone; oral
3.9
31.2
112
352
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.0
31.0
50
79
R03AL08
ATC
vilanterol, umeclidinium bromide and fluticasone furoate; inhalant
11.4
29.9
32
30
R03BA02
ATC
budesonide; inhalant
3.6
29.4
124
433
A15.0
ICD-10 Finland
Tuberculosis of lung, confirmed by sputum microscopy with or without culture
+∞
28.4
27
*
R95
ICPC
Chron obstructive pulmonary disease
7.3
26.3
40
59
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
7.2
25.9
40
60
TDM10
NOMESCO Finland
Puncture of maxillary antrum
7.6
25.8
38
54
J01FA06
ATC
roxithromycin; oral
2.8
25.8
237
1273
J45
ICD-10 Finland
Asthma
4.2
23.6
69
185
J01FA09
ATC
clarithromycin; systemic
2.8
22.7
173
832
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
6.0
22.2
41
74
R02
ICPC
Shortness of breath/dyspnoea
3.2
21.5
102
377
3101A
ICD-9 Finland
Specific nonpsychotic mental disorders following organic brain damage, Organic personality syndrome
+∞
21.0
20
*
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
4.4
20.6
55
137
UDH02
NOMESCO Finland
Rhinopharyngoscopy
4.3
20.1
56
144
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
5.2
19.8
43
90
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.8
19.8
66
194
B44.1
ICD-10 Finland
Other pulmonary aspergillosis
208.8
19.7
20
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
19.0
118
504
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.2
18.8
87
315
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
5.1
18.6
41
87
J01AA02
ATC
doxycycline; systemic
3.2
18.5
385
2901
R03BA08
ATC
ciclesonide; inhalant
3.9
18.0
58
166
R03AK07
ATC
formoterol and budesonide; inhalant
2.8
17.8
106
441
J22
ICD-10 Finland
Unspecified acute lower respiratory infection
4.1
17.3
50
132
WW200
NOMESCO Finland
Immunization
6.8
16.8
27
42
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
16.1
16.4
26
17
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
16.4
220
1327
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
17.6
16.3
25
15
R03AK11
ATC
formoterol and fluticasone; inhalant
7.4
16.3
24
34
R50.9
ICD-10 Finland
Fever, unspecified
2.8
16.0
98
412
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
7.3
15.4
23
33
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
6.6
15.2
25
40
R05
ICPC
Cough
2.4
14.7
140
724
J01GB01
ATC
tobramycin; inhalant, parenteral
+∞
14.7
14
*
J01FA10
ATC
azithromycin; systemic
2.2
14.5
257
1707
R01AD08
ATC
fluticasone; nasal
2.3
14.2
136
703
J41.1
ICD-10 Finland
Mucopurulent chronic bronchitis
55.1
13.9
16
*
R03DC01
ATC
zafirlukast; oral
11.4
13.7
25
23
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.4
13.7
53
171
R05
ICD-10 Finland
Cough
2.3
13.2
121
611
R28
ICPC
Limited function/disability (R)
11.5
13.2
24
22
R06.0
ICD-10 Finland
Dyspnoea
2.2
13.1
161
918
A03
ICPC
Fever
2.6
12.9
88
388
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
12.9
171
1004
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.2
12.8
145
799
R96
ICPC
Asthma
3.0
12.8
61
223
A15.1
ICD-10 Finland
Tuberculosis of lung, confirmed by culture only
+∞
12.6
12
*
348
Kela drug reimbursment
Roflumilast
133.6
12.5
13
*
R01AD09
ATC
mometasone; nasal
2.1
12.5
209
1334
GAA10
NOMESCO Finland
Intercostal insertion of pleural drainage tube
6.0
12.4
22
38
JN4AD
NOMESCO Finland
Body CT examination
2.6
12.4
79
337
M05BA04
ATC
alendronic acid; oral
2.7
12.1
72
296
A02BC02
ATC
pantoprazole; systemic
2.2
12.1
336
2569
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
4.3
12.1
32
79
SPAT1017
SPAT
Examination of colour vision
66.7
11.7
13
*
R03DX07
ATC
roflumilast; oral
123.0
11.5
12
*
WX892
NOMESCO Finland
Monitored bed care
3.2
11.4
49
168
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.4
11.4
42
131
J01FA15
ATC
telithromycin; oral
3.0
11.3
54
197
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
4.7
11.1
26
58
J02AC01
ATC
fluconazole; systemic
2.0
11.1
176
1091
4859X
ICD-9 Finland
Bronchopneumonia, organism unspecified[PNEUMONIA NUD]
5.6
11.0
21
39
R24
ICPC
Haemoptysis
18.4
10.8
16
9
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
13.3
10.7
18
14
J20
ICD-10 Finland
Acute bronchitis
2.7
10.7
63
257
J40
ICD-10 Finland
Bronchitis, not specified as acute or chronic
5.0
10.6
23
48
XQ800
NOMESCO Finland
Prick test
3.3
10.5
41
133
A31.89
ICD-10 Finland
Other mycobacterial infections
112.5
10.5
11
*
A31.80
ICD-10 Finland
Oral infection caused by Mycobacterium intracellulare
112.5
10.5
11
*
A01AB04
ATC
amphotericin B; local oral
3.3
10.4
40
128
J02AC03
ATC
voriconazole; systemic
33.4
10.4
13
*
A16.0
ICD-10 Finland
Tuberculosis of lung, bacteriologically and histologically negative
33.4
10.4
13
*
J01CA04
ATC
amoxicillin; systemic
2.2
10.4
361
2909
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
8.2
10.2
22
28
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
9.5
10.1
20
22
A07AA02
ATC
nystatin; oral
3.1
10.1
43
147
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.2
10.1
107
569
49300
ICD-8 Finland
Asthma, bronchiale
7.9
10.0
22
29
SPAT1255
SPAT
Intravenous administration of medicine
3.1
10.0
44
153
J01MA02
ATC
ciprofloxacin; systemic
1.9
9.9
199
1324
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
5.2
9.7
20
40
XG466
NOMESCO Finland
Sleep oxymetry
4.2
9.6
26
65
B02AA02
ATC
tranexamic acid; systemic
2.4
9.4
68
306
B44.0
ICD-10 Finland
Invasive pulmonary aspergillosis
+∞
9.4
9
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.2
9.3
92
474
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
12.9
8.9
15
12
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
8.9
113
639
R03BB02
ATC
oxitropium bromide; inhalant
10.3
8.6
16
16
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
4.6
8.4
20
45
R03BB07
ATC
umeclidinium bromide; inhalant
13.1
8.4
14
11
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
14.8
8.2
13
9
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
4.5
8.2
20
46
R78
ICPC
Acute bronchitis/bronchiolitis
4.9
8.2
18
38
L04AA06
ATC
mycophenolic acid; systemic
8.4
8.2
17
21
R06AE07
ATC
cetirizine; oral
1.8
8.1
181
1226
R03AL04
ATC
indacaterol and glycopyrronium bromide; inhalant
22.5
8.0
11
5
B90.9
ICD-10 Finland
Sequelae of respiratory and unspecified tuberculosis
22.5
8.0
11
5
ZXE00
NOMESCO Finland
One hour or less
1.8
8.0
178
1204
-60
ICPC
Result test/procedure
3.0
7.9
36
128
127
Kela drug reimbursment
Transplant complication
8.7
7.9
16
19
R01AD05
ATC
budesonide; nasal
2.8
7.8
39
146
A01AB10
ATC
natamycin; local oral
4.0
7.8
22
57
J15.1
ICD-10 Finland
Pneumonia due to Pseudomonas
45.8
7.7
9
*
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.8
7.7
188
1301
4930A
ICD-9 Finland
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA SINE EXACERBATIONE]
25.5
7.6
10
*
B44.8
ICD-10 Finland
Other forms of aspergillosis
81.4
7.4
8
*
R29
ICPC
Respiratory symptom/complaint other
2.8
7.4
39
150
A02BC05
ATC
esomeprazole; systemic
1.7
7.4
192
1350
4912B
ICD-9 Finland
Chronic bronchitis, Obstructive chronic bronchitis[BRONCHITIS OBSTRUCTIVA CUM EMPHYSEMATE]
9.6
7.3
14
15
J01XB01
ATC
colistin; inhalant, parenteral
+∞
7.3
7
*
E84.0
ICD-10 Finland
Cystic fibrosis with pulmonary manifestations
+∞
7.3
7
*
R01AD58
ATC
fluticasone, combinations; nasal
2.0
7.3
93
524
J01DA08
ATC
[U] cefaclor
2.6
7.2
41
164
N02AA01
ATC
morphine; systemic, rectal
4.0
7.1
20
52
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.2
7.0
63
312
R03AL11
ATC
formoterol, glycopyrronium bromide and budesonide; inhalant
14.1
6.9
11
8
TPH04
NOMESCO Finland
Cathetrisation of vein
1.9
6.9
110
668
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
3.3
6.8
25
78
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
3.4
6.8
24
73
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
4.0
6.8
19
49
Z2221
NOMESCO Finland
Medical doctor
1.8
6.7
120
752
R06.2
ICD-10 Finland
Wheezing
3.2
6.7
26
84
4900A
ICD-9 Finland
Bronchitis, not specified as acute or chronic[BRONCHITIS NUD]
22.9
6.7
9
*
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
4.1
6.7
18
45
M05BA06
ATC
ibandronic acid; systemic
4.1
6.7
18
45
N02AX02
ATC
tramadol; systemic, rectal
1.7
6.7
201
1459
Z2446
NOMESCO Finland
Social worker
2.7
6.6
36
141
J15.8
ICD-10 Finland
Other bacterial pneumonia
12.5
6.6
11
9
R11
ICD-10 Finland
Nausea and vomiting
2.3
6.6
52
243
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
6.3
6.5
16
26
L04AD01
ATC
ciclosporin; systemic
6.3
6.5
16
26
4940A
ICD-9 Finland
Bronchiectasis[BRONCHIECTASIAE]
70.8
6.4
7
*
R05DA20
ATC
opium alkaloids and derivatives - combinations
1.8
6.4
122
778
H02AB09
ATC
hydrocortisone; systemic
4.2
6.4
17
42
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
3.7
6.4
20
56
J31.0
ICD-10 Finland
Chronic rhinitis
2.5
6.4
42
181
C03CA01
ATC
furosemide; systemic
1.7
6.3
181
1292
F17.20
ICD-10 Finland
Addiction relationship caused by tobacco addiction relationship currently independent
18.3
6.3
9
5
J32.4
ICD-10 Finland
Chronic pansinusitis
7.2
6.3
14
20
B05XA03
ATC
sodium chloride; parenteral
+∞
6.3
6
*
R05CB13
ATC
dornase alfa (desoxyribonuclease); inhalant
+∞
6.3
6
*
A15.2
ICD-10 Finland
Tuberculosis of lung, confirmed histologically
+∞
6.3
6
*
304
Kela drug reimbursment
Dornase alfa
+∞
6.3
6
*
A31.1
ICD-10 Finland
Cutaneous mycobacterial infection
+∞
6.3
6
*
0310A
ICD-9 Finland
Diseases due to other mycobacteria, Pulmonary
+∞
6.3
6
*
J44
ICD-10 Finland
Other chronic obstructive pulmonary disease
5.2
6.2
18
36
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
27.1
6.2
8
*
XG474
NOMESCO Finland
Exhalation nntrogen oxide
4.1
6.2
17
43
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.5
6.2
38
158
R4190
NOMESCO Finland
Nutritional therapy
3.4
6.2
22
67
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
3.1
6.2
26
88
M05BB03
ATC
alendronic acid and colecalciferol; oral
3.5
6.2
21
62
A01AB09
ATC
miconazole; local oral
2.2
6.2
51
243
N06AA09
ATC
amitriptyline; systemic
2.2
6.1
50
237
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.0
6.1
67
357
R03AL03
ATC
vilanterol and umeclidinium bromide; inhalant
6.8
6.1
14
21
R99
ICPC
Respiratory disease other
5.3
6.1
17
33
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.3
6.0
47
219
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
208
139
26.92
253.69
10.2
2.9
—
—
—
0
0
105
38
35.71
159.93
14.3
3.1
—
—
—
0
0
76
11
82.89
141.94
15.9
5.5
—
—
—
0
0
72
23
37.06
112.89
2.0
1.3
2.46
0.14
u/ml
1.49
53
13
105
89
15.07
107.79
2.0
1.5
—
—
—
0
0
98
74
16.64
107.50
1.9
1.5
—
—
—
0
0
100
92
13.68
97.25
2.8
1.3
—
—
—
0
0
73
46
18.74
87.47
1.3
1.3
—
—
—
0
0
84
77
13.18
81.37
1.8
1.6
—
—
—
0
0
79
66
14.30
81.02
1.8
1.6
—
—
—
0
0
63
41
17.70
73.97
1.9
1.5
—
—
—
0
0
121
207
7.62
71.89
2.1
1.2
165.99
345.76
u/ml
0.69
115
193
80
106
8.96
58.81
2.5
1.6
—
—
—
0
0
81
109
8.84
58.80
2.6
1.6
—
—
—
0
0
64
69
10.64
54.95
2.6
1.7
—
—
—
0
0
129
314
5.35
51.98
3.3
2.8
10.59
10.54
g/l
0.04
123
284
49
50
10.87
43.50
2.6
1.5
—
—
—
0
0
35
20
18.89
43.28
1.9
1.7
—
—
—
0
0
35
21
17.98
42.28
1.7
1.2
—
—
—
0
0
37
26
15.41
41.24
1.9
1.5
—
—
—
0
0
186
722
3.68
38.76
3.4
1.9
—
—
—
0
0
44
54
8.92
33.92
2.4
1.6
—
—
—
0
0
33
31
11.41
30.78
2.0
1.7
—
—
—
0
0
166
696
3.19
29.17
8.0
3.0
0.81
0.82
mmol/l
0.99
161
658
30
33
9.67
25.00
2.0
1.7
—
—
—
0
0
30
33
9.67
25.00
2.0
1.7
—
—
—
0
0
30
33
9.67
25.00
2.0
1.7
—
—
—
0
0
335
2179
3.09
24.91
21.2
9.2
4.81
4.17
e9/l
4.21
321
1890
133
545
3.04
23.65
3.1
1.8
—
—
—
0
0
35
19
19.85
23.43
1.9
1.6
—
—
—
0
0
123
507
2.96
21.41
3.0
1.9
—
—
—
0
0
91
323
3.28
20.43
1.9
1.6
—
—
—
0
0
49
116
4.62
19.55
2.1
1.5
0.17
0.06
iu/ml
—
5
22
48
113
4.63
19.28
1.8
1.5
—
—
—
0
0
74
242
3.46
18.86
5.4
3.6
1.99
1.89
mmol/l
0.07
59
185
316
2154
2.56
18.58
15.3
6.5
9.22
11.57
umol/l
8.68
309
2046
82
292
3.21
18.20
2.1
1.4
—
—
—
0
0
40
85
5.07
18.12
15.5
5.7
137.37
157.10
iu/ml
—
8
10
28
43
6.88
17.67
3.0
1.7
—
—
—
0
0
150
751
2.49
17.32
1.8
1.6
2.63
2.58
g/l
0.11
106
410
28
44
6.72
17.30
3.0
1.7
—
—
—
0
0
54
158
3.75
16.19
3.6
1.8
—
—
—
0
0
33
68
5.16
15.45
1.8
1.2
—
—
—
0
0
33
68
5.16
15.45
1.8
1.2
—
—
—
0
0
23
16
15.07
14.20
2.1
1.9
—
—
—
0
0
23
16
15.07
14.20
2.1
1.9
—
—
—
0
0
23
16
15.07
14.20
2.1
1.9
—
—
—
0
0
23
16
15.07
14.20
2.1
1.9
—
—
—
0
0
17
5
35.23
13.59
2.6
1.4
—
—
—
0
0
24
21
12.00
13.45
3.8
2.4
—
—
—
0
0
48
147
3.54
13.42
3.0
1.6
—
—
—
0
0
303
2191
2.17
13.14
12.2
7.0
1.22
1.21
mmol/l
0.12
256
1860
24
45
5.58
12.43
1.1
1.1
—
—
—
0
0
278
1974
2.06
12.28
11.7
6.2
1.22
1.21
mmol/l
0.29
265
1787
18
12
15.56
11.40
2.3
2.2
—
—
—
0
0
18
12
15.56
11.40
2.3
2.2
—
—
—
0
0
358
2846
2.25
11.10
13.1
4.4
19.04
13.47
mm/h
6.95
351
2616
177
1099
2.00
11.09
2.6
2.3
3.00
3.00
mg/l
0.00
155
932
18
13
14.36
11.06
2.4
2.1
—
—
—
0
0
30
76
4.16
10.93
1.5
1.3
—
—
—
0
0
262
1894
1.91
10.17
6.5
4.8
33.23
35.27
g/l
5.65
245
1765
81
382
2.37
10.16
1.9
3.0
64.21
66.20
g/l
1.29
70
348
28
72
4.08
10.01
1.4
1.1
—
3.81
—
0
7
237
1698
1.83
9.07
3.5
3.0
112.69
129.82
ug/l
0.96
220
1548
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
36
121
3.15
8.67
4.1
2.4
0.41
0.37
iu/ml
0.30
22
70
30
90
3.50
8.64
1.9
2.0
124.76
127.64
g/l
0.21
21
75
114
664
1.96
8.20
1.3
1.3
76.39
36.83
iu/ml
0.57
38
207
57
258
2.38
7.78
2.4
1.7
—
—
—
0
0
250
1879
1.74
7.63
3.5
2.6
—
—
—
0
0
203
1459
1.71
7.13
3.8
3.2
1251.09
1467.89
ng/l
0.54
186
1247
263
2029
1.71
7.09
18.3
15.6
1.25
1.29
inr
0.55
227
1714
18
32
5.81
6.83
1.6
1.3
51.67
51.63
u/l
0.00
18
27
116
719
1.83
6.76
3.2
2.6
11.05
12.45
umol/l
1.47
106
668
70
369
2.06
6.57
8.0
4.1
1.23
1.23
mmol/l
0.11
65
313
38
161
2.49
5.99
1.9
2.7
0.67
0.88
g/l
0.16
33
137
19
54
3.63
5.94
1.6
1.3
—
—
—
0
0
102
634
1.79
5.81
3.4
2.6
18.13
22.16
%
3.20
93
594
83
486
1.87
5.73
8.7
7.9
2.79
0.97
mmol/l
3.31
75
401
91
549
1.82
5.72
10.8
5.2
1.04
1.06
mmol/l
0.30
85
498
173
1246
1.63
5.70
4.8
3.1
29.10
33.39
u/l
1.25
167
1171
290
2370
1.63
5.63
9.5
5.1
6.49
6.75
mmol/l
1.62
283
2252
16
42
3.91
5.58
1.4
1.1
—
9.63
—
0
12
105
667
1.75
5.53
3.4
2.6
2.25
2.25
g/l
0.03
95
620
127
851
1.69
5.51
2.5
1.6
1.26
1.42
mg/l
0.21
102
675
36
155
2.44
5.49
1.7
3.5
19.27
3.07
ratio
0.42
16
88
37
166
2.34
5.17
1.9
3.8
162.44
92.13
mg/l
0.24
29
137
37
166
2.34
5.17
1.9
3.8
31.44
54.98
mg/l
0.71
29
138
23
84
2.83
4.85
5.1
2.6
8.93
8.36
pmol/l
0.09
23
84
8
7
11.60
4.80
1.1
1.1
102.63
101.57
%
—
8
7
20
68
3.03
4.77
1.2
1.3
—
—
—
0
0
194
1484
1.54
4.72
4.8
3.3
2.35
2.36
mmol/l
0.44
182
1334
93
601
1.69
4.55
1.3
1.3
11.79
13.04
u/ml
0.04
24
211
15
44
3.49
4.50
4.3
1.6
2.27
0.22
mmol/l
1.22
15
44
30
133
2.35
4.32
1.4
1.4
277.13
296.95
ug/g
0.16
16
71
11
20
5.61
4.31
2.6
2.6
534.64
882.40
u/ml
1.11
11
20
173
1319
1.51
4.14
3.3
2.5
57.13
65.10
u/l
0.54
164
1221
175
1342
1.50
4.06
1.8
1.7
20.53
21.21
nmol/l
0.23
148
1098
70
436
1.72
3.90
6.0
3.6
—
—
—
0
0
58
345
1.78
3.79
4.0
3.2
178.79
182.50
ng/l
0.03
53
314
72
458
1.68
3.71
8.3
3.3
3.08
1.69
mmol/l
2.12
66
375
156
1186
1.48
3.71
6.1
3.3
0.31
0.54
e6/l
0.91
133
886
119
855
1.53
3.71
1.3
1.3
1.25
1.67
u/ml
0.42
22
207
177
1381
1.46
3.68
5.9
3.4
37.53
87.36
e6/l
0.48
150
1083
17
62
2.81
3.63
1.2
1.2
164.00
162.27
au/ml
—
5
20
24
106
2.34
3.52
3.6
3.5
2.54
2.56
index
0.00
13
55
72
467
1.64
3.45
2.9
3.0
6.12
8.56
umol/l
1.04
66
417
12
32
3.82
3.41
1.8
1.2
—
—
—
0
0
17
65
2.68
3.34
1.4
1.2
—
—
—
0
0
204
1665
1.41
3.21
6.0
4.2
66.29
60.03
ng/l
0.05
161
1294
22
100
2.26
3.04
1.2
1.2
—
—
—
0
0
29
149
2.01
2.97
1.5
1.2
—
—
—
0
0
219
1829
1.38
2.93
3.3
2.5
83.54
79.16
nmol/l
1.55
200
1601
25
125
2.06
2.76
1.6
1.6
—
—
—
0
0
332
3604
0.70
2.70
6.3
6.3
2.50
2.61
mmol/l
1.62
297
3267
10
31
3.28
2.53
1.5
1.3
—
—
—
0
0
36
213
1.75
2.44
1.9
1.8
1.82
1.52
g/l
1.11
31
191
10
33
3.08
2.37
1.1
1.2
—
—
—
0
0
10
33
3.08
2.37
1.1
1.2
—
—
—
0
0
161
1314
1.35
2.36
3.3
2.1
132.29
197.41
u/l
1.78
154
1229
116
905
1.38
2.25
2.5
3.0
2.49
2.46
mmol/l
1.91
105
817
150
1219
1.35
2.25
6.0
4.4
0.00
0.00
estimate
0.50
69
422
10
35
2.90
2.22
1.0
1.2
—
—
—
0
0
7
19
3.72
2.16
1.3
1.4
—
—
—
0
0
7
19
3.72
2.16
1.3
1.4
—
—
—
0
0
23
123
1.92
2.15
1.2
1.3
—
—
—
0
0
325
3506
0.74
2.14
5.6
5.3
1.59
1.48
mmol/l
3.46
288
3164
328
3529
0.74
2.07
5.7
5.4
4.48
4.54
mmol/l
0.59
289
3207
7
20
3.54
2.06
3.1
1.8
66.71
63.85
ug/l
—
7
20
46
305
1.57
2.05
2.8
2.9
75.87
59.76
ml/min/173m2
1.64
24
131
107
837
1.36
2.03
5.1
4.1
366.57
261.47
ng/l
0.29
91
703
104
810
1.37
2.03
1.9
1.8
1339.82
1181.97
nmol/l
0.87
78
591
28
164
1.75
2.00
2.6
1.6
7.19
11.48
iu/ml
—
7
38
18
91
2.02
1.98
2.7
1.5
—
—
—
0
0
7
21
3.37
1.97
1.1
1.9
—
—
—
0
0
54
376
1.50
1.94
2.6
2.5
34.59
34.61
u/l
0.00
46
306
6
16
3.79
1.94
1.2
1.1
—
16.92
—
0
5
331
3539
0.76
1.81
6.0
5.6
5.84
6.03
mmol/l
2.21
303
3175
34
218
1.61
1.76
1.6
1.4
—
—
—
0
0
6
18
3.36
1.75
1.0
1.1
—
—
—
0
0
238
2113
1.27
1.73
5.7
4.4
0.07
7.48
estimate
0.79
74
468
5
13
3.88
1.72
1.0
1.2
—
—
—
0
0
236
2095
1.27
1.71
5.8
4.4
0.00
0.00
estimate
-0.00
73
447
12
55
2.21
1.69
1.4
1.4
—
—
—
0
0
12
55
2.21
1.69
1.4
1.4
—
—
—
0
0
12
55
2.21
1.69
1.4
1.4
—
—
—
0
0
6
19
3.19
1.66
1.7
1.6
—
—
—
0
0
6
19
3.19
1.66
1.7
1.6
—
—
—
0
0
7
25
2.83
1.65
1.3
1.4
—
—
—
0
0
12
56
2.17
1.62
1.4
1.4
—
—
—
0
0
5
14
3.60
1.62
1.0
1.1
—
—
—
0
0
239
2135
1.25
1.60
5.8
4.5
0.00
0.70
estimate
0.51
72
434
11
50
2.23
1.58
1.2
1.1
—
—
—
0
0
12
57
2.14
1.56
1.4
1.4
—
—
—
0
0
12
57
2.14
1.56
1.4
1.4
—
—
—
0
0
18
100
1.83
1.55
2.6
2.6
173.60
101.58
ug/min
0.45
12
63
114
937
1.29
1.52
1.8
1.7
462.63
23351361.09
pmol/l
0.75
89
758
11
51
2.19
1.51
1.4
1.1
1.40
1.47
u/ml
—
5
15
13
65
2.03
1.50
2.1
2.7
36.43
23.73
mg/l
—
7
32
327
3476
0.78
1.48
7.0
7.1
39.86
39.97
mmol/mol
0.08
305
3212
7
28
2.52
1.45
1.0
1.2
—
—
—
0
0
9
39
2.33
1.43
2.0
1.4
—
—
—
0
0
120
1003
1.27
1.40
5.3
3.0
341.98
350.24
umol/l
0.38
111
854
7
29
2.44
1.39
1.1
1.2
—
—
—
0
0
7
29
2.44
1.39
1.1
1.2
—
—
—
0
0
7
29
2.44
1.39
1.1
1.2
—
—
—
0
0
117
977
1.27
1.37
3.4
2.3
—
—
—
0
0
310
2879
1.25
1.36
5.0
4.3
15.20
14.98
pmol/l
0.79
285
2571
5
17
2.96
1.36
2.0
1.1
—
—
—
0
0
5
18
2.80
1.29
1.0
1.1
—
—
—
0
0
10
48
2.11
1.28
1.5
1.4
9148.00
55067.36
e6/l
—
5
22
9
44
2.07
1.27
2.8
2.4
—
—
—
0
0
8
36
2.24
1.25
1.1
1.2
—
—
—
0
0
6
25
2.42
1.24
1.3
1.4
—
—
—
0
0
49
370
1.36
1.19
2.2
2.4
8.00
7.41
ug/l
0.09
41
320
6
26
2.32
1.19
1.5
1.4
59.83
84.46
umol/l
—
6
26
6
26
2.32
1.19
2.3
1.2
—
—
—
0
0
8
38
2.12
1.19
3.0
3.1
333.38
948.18
mg
—
8
38
88
724
1.27
1.17
4.8
3.0
0.86
1.33
e6/l
1.06
55
406
61
478
1.32
1.17
1.3
1.5
—
—
—
0
0
15
87
1.75
1.16
1.1
1.5
—
—
—
0
0
212
1924
1.19
1.08
2.3
2.2
95.07
96.70
pmol/l
0.21
122
975
251
2313
1.19
1.07
7.4
3.3
47.48
51.86
u/l
0.41
240
2140
10
52
1.94
1.07
1.1
1.8
11.30
11.12
mmol/l
—
10
52
31
221
1.43
1.06
17.8
10.6
15.43
15.70
%
0.25
31
211
318
3352
0.83
1.05
4.7
4.5
1.14
1.26
mmol/l
3.78
277
2987
79
948
0.80
1.04
4.2
4.7
1.01
1.02
kg/l
2.33
49
654
18
114
1.60
1.04
2.4
1.6
—
—
—
0
0
7
34
2.08
1.03
1.1
1.2
—
—
—
0
0
5
23
2.19
0.98
1.0
1.0
—
—
—
0
0
375
3607
1.24
0.92
45.9
17.4
23.07
24.55
mg/l
0.52
356
3025
80
671
1.23
0.91
5.2
3.2
3.00
2.87
e6/l
0.04
46
353
6
29
2.08
0.89
1.3
1.2
115.83
101.83
pmol/l
—
6
29
37
282
1.34
0.88
5.2
7.8
27.51
24.55
mmol/l
2.38
37
269
15
95
1.60
0.88
1.5
1.2
—
—
—
0
0
39
498
0.76
0.86
8.1
7.4
—
—
—
0
0
78
914
0.82
0.83
3.9
4.8
19.73
22.02
%
0.66
33
482
56
679
0.80
0.82
3.4
3.4
0.91
0.84
ug/l
0.09
39
454
10
58
1.74
0.80
19.3
6.6
8.15
6.67
mmol/l
—
10
48
22
158
1.41
0.76
2.0
1.3
—
—
—
0
0
376
3866
0.84
0.70
59.8
27.0
129.57
133.05
g/l
5.23
376
3816
376
3865
0.84
0.69
61.2
27.3
39.40
39.73
%
0.73
376
3815
376
3864
0.84
0.68
59.0
26.8
91.75
91.50
fl
0.51
376
3817
7
44
1.60
0.65
1.3
1.1
—
—
—
0
0
13
189
0.68
0.65
1.8
3.2
50.23
2056.50
u/ml
1.44
13
164
8
52
1.55
0.59
1.4
1.6
—
—
—
0
0
11
73
1.52
0.56
1.2
1.5
233.80
283.82
miu/ml
—
5
28
26
204
1.29
0.55
1.5
1.4
—
36.96
—
0
19
16
118
1.37
0.51
1.6
1.2
—
—
—
0
0
14
101
1.40
0.50
1.5
1.3
—
—
—
0
0
27
218
1.25
0.47
3.2
3.3
27.54
24.78
mmol/l
2.50
27
210
12
85
1.42
0.47
2.0
1.8
2.17
76.22
iu/l
—
6
33
39
454
0.85
0.42
1.5
1.4
—
—
—
0
0
5
33
1.52
0.41
1.4
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
328.00
—
0
10
0
17
0.00
0.40
0.0
1.2
—
156.49
—
0
17
59
524
1.14
0.40
4.7
5.2
37.24
32.11
%
2.53
41
322
106
1146
0.90
0.39
6.0
5.8
2.77
3.13
ug/l
0.18
92
1015
5
36
1.39
0.38
1.4
1.1
—
—
—
0
0
144
1531
0.91
0.38
2.2
1.9
1.22
1.30
mmol/l
0.63
117
1247
15
120
1.26
0.30
1.7
1.2
—
—
—
0
0
22
185
1.20
0.29
1.0
1.1
—
—
—
0
0
10
77
1.31
0.26
2.6
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
8
102
0.78
0.21
1.5
1.7
49.50
40.85
nmol/l
—
8
97
346
3411
1.06
0.19
6.3
5.5
1.95
2.00
mu/l
0.39
323
3081
29
261
1.12
0.19
2.0
2.2
11.86
13.78
nmol/l
0.51
23
238
7
58
1.21
0.18
1.4
1.4
0.50
0.65
nmol/l
—
7
53
119
1142
1.06
0.18
6.3
3.9
3.73
0.07
estimate
0.48
67
361
166
1608
1.05
0.18
5.8
4.5
0.00
0.03
estimate
1.47
65
378
11
91
1.21
0.17
2.5
2.2
—
—
—
0
0
355
3505
1.06
0.17
35.9
17.5
78.12
74.59
ml/min/173m2
2.71
346
3268
147
1421
1.05
0.17
4.2
3.4
6.02
7.15
mmol/l
3.13
130
1182
19
215
0.88
0.17
1.3
1.2
89.04
139.76
u/ml
—
9
76
5
70
0.71
0.17
1.4
1.4
—
—
—
0
0
8
72
1.11
0.16
1.3
1.2
0.93
0.82
nmol/l
—
8
59
10
85
1.18
0.12
1.1
1.2
—
11.92
—
0
9
15
133
1.13
0.12
1.1
1.3
0.45
0.29
mg/l
—
5
51
6
54
1.11
0.09
1.0
1.0
—
—
—
0
0
6
55
1.09
0.09
2.5
1.3
—
—
—
0
0
5
60
0.83
0.08
1.2
1.6
1106.60
863.21
mu/l
—
5
47
7
83
0.84
0.07
1.4
1.6
167.57
230.00
pmol/l
—
7
75
11
101
1.09
0.04
1.1
1.3
—
—
—
0
0
19
198
0.96
0.02
2.6
2.1
—
—
—
0
0
182
1828
0.99
0.01
3.5
2.8
—
—
estimate
—
0
0
16
165
0.97
0.00
1.8
2.1
3.01
3.35
mmol/l
0.64
11
120
24
235
1.02
0.00
1.7
2.3
2.79
3.38
ratio
1.46
18
191
20
204
0.98
0.00
5.4
2.9
43.40
115.24
u/ml
0.64
20
199
18
181
0.99
0.00
2.7
2.0
—
—
—
0
0
143
1433
1.00
0.00
5.4
4.1
10.93
10.20
mg/mmol
0.07
96
895
0
5
0.00
-0.00
0.0
1.2
—
6.12
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
1.19
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
11.67
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
44.80
—
0
5
0
6
0.00
-0.00
0.0
3.7
—
96.18
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
0.18
—
0
9
0
7
0.00
-0.00
0.0
1.7
—
8.53
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint MYCOBLUNGATYPICA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| MYCOBLUNGATYPICA | 1.744 [1.51, 2.02] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.209 |
During the follow-up period (1.1.1998 — 31.12.2019), 571 out of 1246 females with MYCOBLUNGATYPICA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| MYCOBLUNGATYPICA | 3.148 [2.47, 4.01] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 490 out of 842 males with MYCOBLUNGATYPICA died.
Mortality risk
Mortality risk for people of age
years, who have MYCOBLUNGATYPICA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.123% | 0.602% |
| 5 | 0.936% | 3.554% |
| 10 | 2.477% | 8.216% |
| 15 | 5.023% | 15.414% |
| 20 | 8.501% | 25.509% |
Relationships between endpoints
↥Index endpoint: MYCOBLUNGATYPICA – Atypical mycobacterium lung infection
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data